CALCA and migraine disorder: Results from clinical studies with small molecule CGRP-antagonists (e.g., olcegepant and telcagepant) as well as monoclonal antibodies (mAbs) neutralizing CGRP or blocking its receptor, have demonstrated that targeting the CGRP pathway provides clinical benefit to individuals with migraine.